) vaccines division, Sanofi Pasteur, recently announced that
Cdiffense, a phase III program, has been initiated. Sanofi is
working on developing a vaccine for the prevention of primary
symptomatic Clostridium difficile infection (CDI). The program
aims to assess the safety, efficacy and immunogenicity of the CDI
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
A randomized, observer-blind, placebo-controlled, multi-center,
multi-national, phase III trial has stared enrolling patients
under the Cdiffense program. The trial will enroll up to 15,000
volunteers aged above 50 years, who have received systemic
antibiotics in the past year and are planning to be hospitalized
or were hospitalized at least twice before.
Earlier this year, Sanofi's vaccine portfolio received a boost
when the European Commission approved its 6-in-1 pediatric
vaccine Hexyon/Hexacima (DTaP-IPV-Hib-HepBvaccine).
The 6-in-1 vaccine is indicated for the prevention of diphtheria,
tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis
and invasive infections caused by haemophilus influenzaetype b in
We note that Sanofi possesses one of the world's leading vaccine
operations, with total sales of €3.9 billion in 2012. The
company's portfolio includes pediatric vaccines, influenza
vaccines, adult and adolescent booster vaccines, meningitis
vaccines, and travel and endemic vaccines. Sanofi also has a
strong position in both seasonal and pre-pandemic influenza
Sanofi continues to expand its vaccine business. We expect a
significant ramp in vaccine sales over the next several years.
Sanofi carries a Zacks Rank #3 (Hold). Sanofi is looking to
combat the generic threat confronting most of its key drugs by
signing deals and making acquisitions. We are pleased with
Sanofi's efforts to develop its pipeline and believe that newly
approved products in Sanofi's portfolio holds huge commercial
Companies that currently look attractive include
Biogen Idec Inc.
Gilead Sciences Inc.
), carrying a Zacks Rank #1 (Buy).